Imricor Medical Systems, Inc. · ASX:IMR
Imricor Medical Systems — Shareholder Meeting (May 2022)
14 slides from Imricor Medical Systems's shareholder meeting presentation, May 4, 2022
Slide 1: Welcome to the Imricor Annual Meeting
For personal use only Welcome to the Wednesday, 4 May 2022 (AEST) Imricor Annual Meeting Tuesday, 3 May 2022 (CDT)
Slide 2: Please submit questions at any time throughout the meeting
Please submit questions at any time throughout the meeting For personal use only To ask a question select the ‘Q&A’ icon Select the topic your question relates to. Type your question into the chat box at the bottom of the screen and press ‘Send’ Your question will be sent immediately for review 2 Im
Slide 3: Voting online at the virtual meeting
Voting online at the virtual meeting For personal use only When the Chair declares the poll open, select the ‘Vote’ icon and the voting options will appear on your screen To vote, select your voting direction. A tick will appear to confirm receipt of your vote To change your vote, select ‘Click here
Slide 4: Imricor's Board of Directors
Imricor’s Board of Directors For personal use only Steve Wedan Mark Tibbles Anita Messal Peter McGregor President and CEO, Deputy Chair and Lead Non-executive Director Non-executive Director and Chair Independent Director 4 Imricor Annual Meeting 2022
Slide 5: Chair's Address
Chair’s Address For personal use only 5 Imricor Annual Meeting 2022
Slide 6: Delivering on our Strategic Plan
Delivering on our Strategic Plan For personal use only Grow Installed Base More sites 1 to do procedures Expand indications More procedures 2 per site Expand geographies Higher ASP and 3 margin improvement New product development 6 Imricor Annual Meeting 2022
Slide 7: FY21 Highlights
FY21 Highlights • Contracted five new sites across Europe, bringing the total number of sites to fourteen For personal use only • Performed procedures as restrictions allowed through COVID waves • Current contracted site status: Current Site Status Number of Sites Operational 6 Installation complete
Slide 8: FY21 Highlights continued
FY21 Highlights continued • Appointed Regional Health Care Group (RHCG) in Australia to help facilitate TGA and Medsafe approvals For personal use only • Medsafe approval received for all Imricor products in New Zealand • Received TGA approval on Imricor’s Advantage-MR System, Vision-MR catheter und
Slide 9: Site expansion plans underpinned by strong pipeline
Site expansion plans underpinned by strong pipeline Helios Hospital Berlin-Buch, For personal use only Germany Dresden Heart Centre, Germany Maastricht University Medical Centre, The Netherlands Semmelweis University Heart and Helios Leipzig Heart Centre, Vascular Centre, Hungary Germany Amsterdam U
Slide 10: Partnering to drive growth in clinical sites
Partnering to drive growth in clinical sites Imricor has entered into a number of agreements that promote future iCMR site adoption For personal use only 10 Imricor Annual Meeting 2022
Slide 11: Developing product lines to support expanded indications & margin improvement
Developing product lines to support expanded indications & margin improvement Steerable Sheath and For personal use only Transseptal Needle • Preclinical trials underway • Undergoing final device testing • Preparing for approval submission as part of VT trial in 2022 • Preparing for CE mark submissi
Slide 12: A strong and growing market in cardiac ablation
A strong and growing market in cardiac ablation A large global addressable market with high growth potential supported by favourable growth drivers For personal use only Drivers of Global Catheter Ablation Market Breakdown of Ablation Procedures Ablation Procedure Types EU 2019 Ventricular Tachycard
Slide 13: Focus Initiatives for 2022
Focus Initiatives for 2022 Site Growth • For personal use only Increased engagement with Electrophysiologists to drive demand for iCMR labs • Increased engagement with Philips and Siemens sales forces to help deliver the pipeline of iCMR labs Utilisation • Initiate procedures at each contracted site
Slide 14: Disclaimer
Disclaimer The material contained in this presentation is intended to be general background information on Imricor Medical Systems Inc (“Imricor”) and its activities. For personal use only The information is supplied in summary form and is therefore not necessarily complete. It is not intended that
Imricor Medical Systems — Shareholder Meeting (May 2022) on 6ix